"Dipeptidyl Peptidase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine protease that catalyses the release of an N-terminal dipeptide. Several biologically-active peptides have been identified as dipeptidyl peptidase 4 substrates including INCRETINS; NEUROPEPTIDES; and CHEMOKINES. The protein is also found bound to ADENOSINE DEAMINASE on the T-CELL surface and is believed to play a role in T-cell activation.
| Descriptor ID |
D018819
|
| MeSH Number(s) |
D08.811.277.656.350.350.126 D08.811.277.656.959.250 D23.050.301.264.894.160 D23.101.100.894.160
|
| Concept/Terms |
Dipeptidyl Peptidase 4- Dipeptidyl Peptidase 4
- CD26 Antigen
- Antigen, CD26
- Antigens, CD26
- Adenosine Deaminase Complexing Protein 2
- Dipeptidyl-Peptidase IV
- Dipeptidyl Peptidase IV
- CD26 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl Peptidase 4".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl Peptidase 4".
This graph shows the total number of publications written about "Dipeptidyl Peptidase 4" by people in this website by year, and whether "Dipeptidyl Peptidase 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dipeptidyl Peptidase 4" by people in Profiles.
-
Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens. Cytometry B Clin Cytom. 2008 Nov; 74(6):341-8.
-
Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem. 2007 Mar 30; 282(13):10117-10131.
-
Bone marrow progenitors are not the source of expanding oval cells in injured liver. Stem Cells. 2004; 22(6):1049-61.
-
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8.
-
Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res. 2001 Oct 01; 61(19):7204-10.
-
In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res. 2001 Jul; 7(7):2031-40.
-
Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001 Jun; 115(6):885-92.
-
Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer. 1986 Dec 15; 58(12):2617-21.
-
Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein. Am J Clin Pathol. 1986 Dec; 86(6):780-3.
-
Enzymehistochemical staining of T mu lymphocytes for glycyl-proline-4-methoxy-beta-naphthylamide-peptidase (DAP IV). Br J Haematol. 1982 Jun; 51(2):227-34.